What did @daviddemesquita actually say?
The creator described GHK-Cu as "the hair and skin peptide that everyone is obsessed with" and credited it with anti-inflammatory effects, hair follicle growth, and skin elasticity. The most striking claim was that GHK-Cu "tries to protect those good cells, whereas cancer or tumor cells, it tries to get rid of." He also flagged injection site pain as a real downside, suggested diluting with bacteriostatic water, and floated a dosing range of "2.5 milligrams up to 5 milligrams per day," partly justifying it by saying "a lot of us have copper deficiency." He wrapped up by saying nothing should be run indefinitely, which is actually reasonable advice.
Does the science back this up?
Partly. GHK-Cu has a real research base, but most of it is preclinical. The anti-inflammatory and skin remodeling data are the strongest. The cancer claim is the most overstated.
The peptide GHK (glycyl-L-histidyl-L-lysine) binds copper and has been studied since Loren Pickart first described it in human plasma in the 1970s. In tissue culture and animal models, it promotes collagen synthesis and wound healing. Pickart and Margolina (2018, Cosmetics) reviewed a large body of in vitro and animal work showing GHK-Cu activates genes involved in skin repair and modulates inflammation by downregulating TNF-alpha and other cytokines. That part of the creator's claim is well-supported, at least in a preclinical sense.
On hair follicles, a 1993 study by Uno and colleagues showed topical GHK-Cu stimulated hair growth in mice and macaques. There is limited human clinical trial data, but cosmetic formulations have used it for decades based on this foundation.
The cancer claim is where things get messy, and the creator glossed over that messiness entirely.
What did they get wrong (or right)?
The cancer claim is the most problematic thing in this video. The idea that GHK-Cu selectively eliminates tumor cells while protecting healthy ones is not established in human evidence. Some in vitro studies, including work by Maquart et al. (1999, European Journal of Biochemistry), suggested GHK-Cu may reset cancer cell gene expression toward a more normal phenotype. Pickart and Margolina have made similar arguments based on gene array data. But "in vitro suggests a mechanism" is a very long way from "gets rid of cancer cells in your body." The creator presented this as a concrete benefit, not a hypothesis. That framing is irresponsible.
What the creator got right: injection site pain is a documented real-world complaint with reconstituted peptide injections, and suggesting dilution with bacteriostatic water is a practical, harm-reduction response. Noting that it should not be run indefinitely is good instinct, even if he did not explain why.
The dosing range he cited, 2.5 to 5 mg per day, has no established clinical basis. There are no FDA-approved protocols for injectable GHK-Cu, and circulating the "copper deficiency" rationale as a safety justification is not supported by published pharmacology.
What should you actually know?
GHK-Cu is a legitimate research compound with a real preclinical track record in skin repair and inflammation. It is not a proven treatment for hair loss, cancer, or any disease. The gap between "interesting peptide biology" and "here is what it does in your body at injectable doses" is enormous, and most of the internet content about GHK-Cu does not acknowledge that gap.
For skin applications, there is a reasonable cosmetic science case. For systemic injectable use at the doses circulating online, human safety and efficacy data are essentially absent. Pickart's own published reviews are enthusiastic but rely heavily on gene expression studies and extrapolation.
If you are considering GHK-Cu through a telehealth platform, the conversation should include what condition you are actually trying to address, whether there are evidence-based alternatives, and a realistic assessment of what the peptide research actually shows versus what influencers say it shows. The cancer angle especially should not be part of any responsible clinical conversation without a significant caveat about the state of the evidence.